SEARCH

SEARCH BY CITATION

References

  • ACR (2002). American College of Rheumatology subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46: 328346.
  • Argiles JM, Lopez-Soriano FJ (2002). Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1: 245251.
  • Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM et al. (2005). An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 65: 473496.
  • Blanchard F, Chipoy C (2005). Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10: 197204.
  • Bush KA, Farmer KM, Walker JS, Kirkham BW (2002). Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46: 802805.
  • Chung YL, Lee MY, Wang AJ, Yao LF (2003). A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8: 707717.
  • Clair EWS (2002). Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis 61: ii67ii69.
  • Cronstein BN (2005). Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57: 163172.
  • Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N et al. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 2736.
  • Firestein GS (2003). Evolving concepts of rheumatoid arthritis. Nature 423: 356361.
  • Gravallese EM, Goldring SR (2000). Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43: 21432151.
  • Green GS (2000). Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 59: i46i49.
  • Haringman JJ, Ludikhuize J, Tak PP (2004). Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 63: 11861194.
  • Huang N, Katz JP, Martin DR, Wu GD (1997). Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 9: 2736.
  • Hirokawa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V et al. (2005). Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol Ther 4: 379381.
  • Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287299.
  • Johnstone RW (2004). Suberanilohydroxamic acid. Aton pharma. IDrugs 7: 674682.
  • Jou IM, Shiau AL, Chen SY, Wang CR, Shieh DB, Tsai CS et al. (2005). Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum 52: 3944.
  • Jungel A, Baresova V, Ospelt C, Simmen BR, Michel BA, Gay RE et al. (2006). Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 65: 910912.
  • Kapadia RD, Stroup GB, Badger AM, Koller B, Levin JM, Coatney RW et al. (1998). Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis. Technol Health Care 6: 361372.
  • Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 35783588.
  • Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 10: 39233931.
  • Kim SH, Ahn S, Han JW, Lee HW, Lee HY, Lee YW et al. (2004). Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315: 964970.
  • Klinkhoff A (2004). Biological agents for rheumatoid arthritis. Drugs 64: 12671283.
  • Lee DM, Weinblatt ME (2001). Rheumatoid Arthritis. Lancet 358: 903911.
  • Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P et al. (2005). The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: 115.
  • Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. (2002). The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 99: 29953000.
  • Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA et al. (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520527.
  • Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H et al. (2003). Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300: 241246.
  • Mishra N, Brown DR, Olorenshaw IM, Kammer GM (2001). Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 98: 26282633.
  • Mort JS (2005). Histone deacetylases – a new target for suppression of cartilage degradation? Arthritis Res Ther 7: 155156.
  • Mount C, Featherstone J. (2005). Rheumatoid arthritis market. Nat Rev Drug Discov 4: 1112.
  • Mukhopadhyay NK, Weisberg E, Gilchrist D, Bueno R, Sugarbaker DJ, Jaklitsch MT (2006). Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer. Ann Thorac Surg. 81: 10341042.
  • Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H et al. (2004). Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 10: 33653376.
  • Piekarz R, Bates S (2004). A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10: 22892298.
  • Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L et al. (2004). The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 64: 66266634.
  • Quinn MA, Conaghan PG, Emery P (2001). The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology 40: 12111220.
  • Rall LC, Roubenoff R (2004). Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 10: 12191223.
  • Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J et al. (2005). Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 10: 39123922.
  • Ruegsegger P, Koller B, Muller R (1996). A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58: 2429.
  • Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, Devernejoul MC, Boissier MC, Cohen-Solal ME (2004). TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35: 12001207.
  • Salvemini D, Mazzon E, Dugo L, Serraino I, De Sarro A, Caputi AP et al. (2001). Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. Arthritis Rheum 44: 29092921.
  • Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A (2005). Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 116: 816.
  • Sims NA, Green JR, Glatt M, Schlict S, Martin TJ, Gillespie MT et al. (2004). Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 50: 23382346.
  • Walsmith J, Abad L, Kehayias J, Roubenoff R (2004). Tumor necrosis factor-alpha production is associated with less body cell mass in women with rheumatoid arthritis. J Rheumatol 31: 2329.
  • Young DA, Lakey RL, Pennington CJ, Jones D, Kevorkian L, Edwards DR et al. (2005). Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther 7: R503R512.